1 active not recruiting, 1 completed, 1 withdrawn. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Neuromuscular Blocking Agents: new trials by email Literature Review of Neuromuscular Blocking Agents trials Research Report on Neuromuscular Blocking Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Therapeutic Hypothermia in Patients With ARDS Hypothermia, Neuromuscular Blocking Agents, Standard of care - Respiratory Distress Syndrome, Adult | Phase 2 | Active not recruiting | University of Maryland, Baltimore | 340 | 2021-06-29 | 2026-09-09 |
| Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS Hypothermia, Neuromuscular Blocking Agents, Standard of Care - Respiratory Distress Syndrome, Adult, Sars-CoV2 | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2018-05-01 | 2021-04-30 | |
| Strategy of UltraProtective Lung Ventilation With Extracorporeal CO2 Removal for New-Onset Moderate to seVere ARDS ECCO2R will be initiated during the 2-hour run-in time, Neuromuscular blocking agents (NMBA), Ventilation - Moderate Acute Respiratory Distress Syndrome | Phase 1 / Phase 2 | Completed | European Society of Intensive Care Medicine | 95 | 2015-11-01 | 2017-08-04 |
Respiratory Distress Syndrome (2) · Acute Lung Injury (1) · COVID-19 (1)
University of Maryland, Baltimore (2) · European Society of Intensive Care Medicine (1)
United States (2) · Belgium (1)